摘要
目的 研究人类白细胞抗原 (HLA)配型不合造血干细胞移植 (HSCT)治疗恶性血液病的新移植方案。方法 10 0例恶性血液病患者 ,5 6例为高危病例 ,进行HLA配型至少 1个位点不合的亲缘供者HSCT。采用GIAC移植方案 ,即G CSF动员供者干细胞 ,强化、延长的免疫抑制促进植入及预防移植物抗宿主病 (GVHD) ,使用抗胸腺细胞球蛋白 ,以及骨髓及外周血干细胞联合移植。结果 所有患者均达完全供者植入。发生Ⅱ~Ⅳ度急性GVHD(aGVHD) 4 5例 ,累积发生率 4 8.39% ,发生Ⅲ~Ⅳ度aGVHD 12例 ,累积发生率 12 .90 %。 6 1例可评估的患者中 ,发生慢性 (c)GVHD 38例 ,广泛型 11例。复发 12例 ,11例为高危患者 ,3例经供者淋巴细胞输注达再次完全缓解。死亡 2 2例 ,6例死于复发 ,16例死于移植相关合并症。 72例患者无病存活 ,1年预期无病生存率 ,高危组为 (4 7.6 3± 8.4 9) % ,标危组为 (83.5 2± 7.4 1) %。结论 GIAC方案适用于HLA配型不合的HSCT ,是治疗恶性血液病比较安全。
Objective To explore the clinical application of human leukocyte antigen(HLA) mismatched hematopoietic stem cell transplantation(HSCT) for malignant hematological diseases using a new GIAC protocol. Methods One hundred patients with malignant hematological disease received G-CSF mobilization, intensive immunosuppression, ATG and combination of bone marrow and peripheral blood stem cell transplantation at least 1 locus mis-matched hematopoietic stem cell transplant performed with GIAC protocol. The conditioning regimen was intensified and prolonged with combined use of CsA, MMF and ATG for GVHD prophylaxis. Results All patients achieved sustained, full donor-type engraftment. The cumulative incidence of grade Ⅱ~Ⅳ aGVHD was 48.39%,and grade Ⅲ~Ⅳ aGVHD was 12.90%. Thirty-eight patients had cGVHDs which were of extensive type in 11 patients. Twelve patients relapsed, 11 of them were high-risk patients, and 3 returned to CR after donor lymphocyte infusion. Twenty-two patients died, owing to recurrent diseases in 6 and transplant-related complications in 16 cases. Seventy-two patients were alive and disease free, with 1 year disease-free survival probabilities for standard and high risk patients of (83.52±7.41)% and (47.63±8.49)%, respectively. Conclusion The GIAC protocol for at least 1 locus mismatched hematopoietic stem cell transplantation is relatively safe and efficient for patients with hematological malignancies.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2004年第8期453-457,共5页
Chinese Journal of Hematology